Form 4: Gilde Healthcare Reduces LAVA Therapeutics Stake

Gilde Healthcare, a 10% owner and director of LAVA Therapeutics NV, reported multiple sales of common shares in early October 2025.

Summary

• Cooperatieve Gilde Healthcare IV U.A., a 10% owner and director of LAVA Therapeutics NV (LVTX), reported sales of common shares.
• On October 8, 2025, 28,954 common shares were sold at a weighted average price of $1.57 per share.
• On October 9, 2025, 48,169 common shares were sold at a weighted average price of $1.56 per share.
• On October 10, 2025, 49,869 common shares were sold at a weighted average price of $1.55 per share.
• Following these transactions, Cooperatieve Gilde Healthcare IV U.A. directly holds 5,294,178 common shares.
• The sales were executed pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 3

Explanation: The sale of shares by a significant insider and director, even if pre-planned, generally carries a negative sentiment as it can be perceived as a lack of confidence in the company's near-term prospects or valuation. The reduction in holdings by a 10% owner is a notable event.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned sales rather than an immediate reaction to new information.

Negatives

• A significant shareholder and director, Cooperatieve Gilde Healthcare IV U.A., reduced its stake in LAVA Therapeutics NV.
• The sales occurred over three consecutive days, indicating a systematic reduction in holdings.
• The average sale price decreased slightly over the three days, from $1.57 to $1.55 per share.

Risks

• Potential negative market perception due to a 10% owner and director reducing their stake, which could signal a lack of confidence.
• Increased selling pressure on LAVA Therapeutics NV's common shares due to the volume of shares sold by a large holder.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.

Comparison to Industry Standards

• NA

Related Party Transactions

• Sales of common shares by Cooperatieve Gilde Healthcare IV U.A., which is a 10% owner and director of LAVA Therapeutics NV.

Stakeholder Impact

• Shareholders: May interpret the insider sales as a negative signal, potentially leading to downward pressure on the stock price.
• Management: The sales by a director could raise questions internally about the director's long-term commitment or view of the company's trajectory.

Next Steps

• NA

Key Dates

Recommendation

The systematic sale of shares by a 10% owner and director, Cooperatieve Gilde Healthcare IV U.A., over three consecutive days suggests a deliberate reduction in exposure to LAVA Therapeutics NV. While executed under a 10b5-1 plan, such insider selling, especially by a significant holder, often signals a lack of strong conviction in the company's near-term growth or valuation by those with intimate knowledge. This could lead to negative market sentiment and potential downward pressure on the stock price, warranting a 'sell' recommendation for investors to consider reducing their own exposure.

Keywords

LAVA Therapeutics, LVTX, Gilde Healthcare, Form 4, Insider Sale, Beneficial Ownership, Equity Transaction, Director Sale, 10b5-1 Plan